Form 4: Sana Bio CFO Converts RSUs, Sells Shares for Tax

Sana Biotechnology's Acting CFO, Susan D. Wyrick, converted 7,500 restricted stock units into common stock and subsequently sold 2,407 shares to cover tax obligations.

Summary

• Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, Inc., reported transactions involving the company's common stock.
• On January 2, 2026, Wyrick acquired 7,500 shares of common stock through the conversion of restricted stock units (RSUs) at a price of $0.00 per share.
• These RSUs had a vesting schedule of 40% on January 2, 2025, and 60% on January 2, 2026.
• Following this acquisition, Wyrick's direct beneficial ownership stood at 188,290 shares.
• On January 5, 2026, Wyrick disposed of 2,407 shares of common stock at a price of $4.27 per share.
• This disposal was likely to cover tax liabilities associated with the RSU vesting and conversion.
• After all reported transactions, Wyrick's direct beneficial ownership of Sana Biotechnology common stock is 185,883 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation and tax obligations, which are neutral in terms of company-specific sentiment.

Positives

• The vesting of 7,500 restricted stock units represents a successful compensation event for the Acting Chief Financial Officer, aligning executive incentives with company performance.

Negatives

• The sale of 2,407 shares, while common for tax purposes, slightly reduces the insider's direct equity holding in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as RSU vesting and subsequent tax-related sales, are routine occurrences across all industries, particularly in biotechnology companies where equity compensation is a significant component of executive pay.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity holdings and compensation activities, which is generally expected and routine.

Key Dates

Keywords

Sana Biotechnology, SANA, Form 4, insider transaction, restricted stock units, RSU vesting, CFO, stock sale, tax liability